LUCD
Lucid Diagnostics Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-47/100
Last price
0.60
▲ 0.01 (1.13%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.59
Day high
0.61
Day low
0.58
Volume
1.46M
Market cap
$114.57M
P/E (TTM)
—
52W range
0.50 – 1.63
Trailing performance
Returnvs SPY
1W
-25.83%
-27.8%
1M
-36.17%
-37.3%
3M
-38.02%
-42.5%
6M
-46.43%
-64.6%
YTD
-44.95%
-59.2%
1Y
-42.31%
-58.7%
3Y
-48.72%
-131.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on LUCD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
50.61M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 20, 26 | MATHEIS DENNIS Director |
BUY | 245.00K | $245.27K | Direct |
| Feb 20, 26 | SOKOLOV JACQUE J Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | MCGRATH DENNIS M Chief Financial Officer |
STOCK | 470.00K | $0 | Direct |
| Feb 20, 26 | LAPIDUS STANLEY N Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | PALUMBO JOHN R Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | AKLOG LISHAN Chief Executive Officer |
STOCK | 2.17M | $0 | Direct |
| Feb 20, 26 | COX JAMES L Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | MATHEIS DENNIS Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | WHITE DEBRA JAYNE Director |
STOCK | 123.00K | $0 | Direct |
| Feb 20, 26 | O'NEIL SHAUN President |
STOCK | 620.00K | $0 | Direct |
| Feb 20, 26 | GORDON MICHAEL ADAM General Counsel |
STOCK | 300.00K | $0 | Direct |
| Aug 20, 25 | MATHEIS DENNIS Director |
BUY | 100.00K | $101.84K | Direct |
| May 22, 25 | MATHEIS DENNIS Director |
BUY | 350.00K | $457.61K | Direct |
| Feb 20, 25 | SOKOLOV JACQUE J Director |
STOCK | 112.80K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AKLOG LISHAN |
Chief Executive Officer | 3.64M | Stock Award(Grant) |
COX JAMES L |
Director | 405.12K | Stock Award(Grant) |
GORDON MICHAEL ADAM |
General Counsel | 1.00M | Stock Award(Grant) |
LAPIDUS STANLEY N |
Director | 337.39K | Stock Award(Grant) |
MATHEIS DENNIS |
Director | 1.03M | Purchase |
MCGRATH DENNIS M |
Chief Financial Officer | 1.81M | Stock Award(Grant) |
O'NEIL SHAUN |
President | 1.45M | Stock Award(Grant) |
PALUMBO JOHN R |
Director | 338.00K | Stock Award(Grant) |
SOKOLOV JACQUE J |
Director | 320.46K | Stock Award(Grant) |
WHITE DEBRA JAYNE |
Director | 235.80K | Stock Award(Grant) |
Fundamentals
Market cap$114.57M
Enterprise value$105.01M
Revenue (TTM)$5.45M
Gross profit$-1.18M
EBITDA$-49.81M
Net income$-65.01M
EPS (TTM)$-0.44
Free cash flow$-26.43M
Total cash$34.47M
Total debt$24.91M
Book value / share$0.06
Shares outstanding190.95M
Float140.76M
Short % of float8.64%
Dividend yield0.00%
Beta (5Y)1.12
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.64
PEG ratio—
Price / sales—
Price / book10.53
EV / revenue19.29
EV / EBITDA-2.11
Gross margin-21.69%
Operating margin-868.45%
Profit margin0.00%
Return on equity-556.27%
Return on assets-81.63%
Debt / equity227.96
Current ratio1.33
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.71M | $4.35M | $2.43M | $377.00K | +8.3% |
| Operating revenue | $4.71M | $4.35M | $2.43M | $377.00K | +8.3% |
| Cost of revenue | $6.67M | $7.10M | $5.98M | $3.61M | -6.0% |
| Gross profit | -$1.96M | -$2.75M | -$3.55M | -$3.24M | +28.7% |
| Research & development | $5.68M | $5.99M | $7.25M | $11.26M | -5.2% |
| Selling, general & admin | $41.58M | $36.62M | $35.66M | $40.11M | +13.5% |
| Total operating expense | $47.68M | $43.30M | $44.93M | $53.01M | +10.1% |
| Operating income | -$49.64M | -$46.05M | -$48.48M | -$56.25M | -7.8% |
| Net interest income | $364.00K | $296.00K | $8.00K | $80.00K | +23.0% |
| Pre-tax income | -$58.01M | -$45.53M | -$52.67M | -$56.17M | -27.4% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$58.01M | -$45.53M | -$52.67M | -$56.17M | -27.4% |
| Net income to common | -$70.57M | -$53.02M | -$52.67M | -$56.17M | -33.1% |
| Basic EPS | -0.43 | -1.05 | -1.26 | -1.55 | +59.0% |
| Diluted EPS | -0.43 | -1.05 | -1.26 | -1.55 | +59.0% |
| EBIT | -$57.99M | -$45.50M | -$52.25M | -$56.16M | -27.4% |
| EBITDA | -$57.12M | -$44.34M | -$49.75M | -$54.23M | -28.8% |
| Basic shares | 164.11M | 50.50M | 41.76M | 36.17M | +225.0% |
| Diluted shares | 164.11M | 50.50M | 41.76M | 36.17M | +225.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $34.70M | $22.36M | $18.90M | $22.47M | +55.2% |
| Cash & short-term investments | $34.70M | $22.36M | $18.90M | $22.47M | +55.2% |
| Accounts receivable | $643.00K | $45.00K | $45.00K | $17.00K | +1,328.9% |
| Inventory | $353.00K | $341.00K | $278.00K | $111.00K | +3.5% |
| Total current assets | $37.47M | $25.15M | $22.07M | $24.36M | +49.0% |
| Property, plant & equipment | $2.62M | $3.70M | $2.64M | $3.60M | -29.3% |
| Goodwill & intangibles | $315.00K | $736.00K | $1.42M | $3.44M | -57.2% |
| Total assets | $40.45M | $30.71M | $27.27M | $32.51M | +31.7% |
| Total current liabilities | $28.58M | $23.52M | $29.38M | $8.43M | +21.5% |
| Current debt | $24.00M | $18.60M | $13.95M | — | +29.0% |
| Total debt | $25.82M | $21.25M | $15.26M | $2.00M | +21.5% |
| Total liabilities | $29.51M | $25.32M | $29.58M | $9.46M | +16.5% |
| Retained earnings | -$274.33M | -$203.77M | -$150.74M | -$98.08M | -34.6% |
| Shareholder equity | $10.94M | $5.39M | -$2.31M | $23.05M | +102.9% |
| Working capital | $8.89M | $1.62M | -$7.31M | $15.93M | +447.2% |
| Net tangible assets | $10.62M | $4.66M | -$3.73M | $19.60M | +128.2% |
| Shares issued | 131.10M | 63.07M | 42.33M | 40.52M | +107.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$58.01M | -$45.53M | -$52.67M | -$56.17M | -27.4% |
| Depreciation & amortisation | $872.00K | $1.17M | $2.50M | $1.94M | -25.3% |
| Stock-based compensation | $4.49M | $4.53M | $6.82M | $14.99M | -0.9% |
| Change in working capital | -$2.81M | -$4.43M | $5.67M | $8.91M | +36.7% |
| Operating cash flow | -$46.48M | -$44.14M | -$32.82M | -$29.68M | -5.3% |
| Capital expenditure | -$197.00K | -$646.00K | -$221.00K | -$908.00K | +69.5% |
| Investing cash flow | -$197.00K | -$646.00K | -$221.00K | -$4.11M | +69.5% |
| Financing cash flow | $59.03M | $48.25M | $29.46M | $2.61M | +22.3% |
| Free cash flow | -$46.68M | -$44.79M | -$33.04M | -$30.59M | -4.2% |
| End cash position | $34.70M | $22.36M | $18.90M | $22.47M | +55.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.47M | $1.26M | $1.50M | $1.21M | $1.16M | +17.4% |
| Operating revenue | $1.47M | $1.26M | $1.50M | $1.21M | $1.16M | +17.4% |
| Cost of revenue | $1.45M | $1.63M | $1.86M | $1.70M | $1.56M | -11.1% |
| Gross profit | $29.00K | -$369.00K | -$356.00K | -$486.00K | -$400.00K | +107.9% |
| Research & development | $1.19M | $1.21M | $1.72M | $1.27M | $1.25M | -1.2% |
| Selling, general & admin | $11.53M | $10.43M | $11.83M | $9.90M | $9.62M | +10.5% |
| Total operating expense | $12.83M | $11.74M | $13.65M | $11.27M | $10.98M | +9.2% |
| Operating income | -$12.80M | -$12.11M | -$14.01M | -$11.76M | -$11.38M | -5.7% |
| Net interest income | $73.00K | $64.00K | $104.00K | $99.00K | $104.00K | +14.1% |
| Pre-tax income | -$11.69M | -$13.91M | -$16.27M | -$10.40M | -$4.44M | +16.0% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$11.69M | -$13.91M | -$16.27M | -$10.40M | -$4.44M | +16.0% |
| Net income to common | -$14.71M | -$23.63M | -$16.27M | -$10.40M | -$7.89M | +37.7% |
| Basic EPS | -0.08 | -0.17 | -0.10 | -0.10 | -0.08 | +52.9% |
| Diluted EPS | -0.08 | -0.17 | -0.10 | -0.10 | -0.08 | +52.9% |
| EBIT | -$11.68M | -$13.90M | -$16.26M | -$10.39M | -$4.43M | +16.0% |
| EBITDA | -$11.46M | -$13.68M | -$16.05M | -$10.18M | -$4.21M | +16.2% |
| Basic shares | 183.12M | 140.10M | 162.66M | 108.18M | 98.99M | +30.7% |
| Diluted shares | 183.12M | 140.10M | 162.66M | 108.18M | 98.99M | +30.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.40M | $27.88M | $34.70M | $47.33M | $31.12M | +19.8% |
| Cash & short-term investments | $33.40M | $27.88M | $34.70M | $47.33M | $31.12M | +19.8% |
| Accounts receivable | $1.09M | $689.00K | $643.00K | $550.00K | $373.00K | +57.9% |
| Inventory | $484.00K | $469.00K | $353.00K | $486.00K | $505.00K | +3.2% |
| Total current assets | $36.62M | $31.36M | $37.47M | $49.84M | $33.83M | +16.8% |
| Property, plant & equipment | $2.21M | $2.50M | $2.62M | $2.88M | $3.19M | -11.6% |
| Goodwill & intangibles | $105.00K | $210.00K | $315.00K | $421.00K | $526.00K | -50.0% |
| Total assets | $38.95M | $34.08M | $40.45M | $53.20M | $38.67M | +14.3% |
| Total current liabilities | $27.52M | $29.39M | $28.58M | $26.21M | $29.43M | -6.4% |
| Current debt | $23.50M | $25.20M | $24.00M | $22.30M | $25.30M | -6.7% |
| Total debt | $24.91M | $26.80M | $25.82M | $24.34M | $27.55M | -7.1% |
| Total liabilities | $28.02M | $30.08M | $29.51M | $27.36M | $30.81M | -6.9% |
| Retained earnings | -$312.68M | -$297.96M | -$274.33M | -$258.07M | -$247.67M | -4.9% |
| Shareholder equity | $10.93M | $4.00M | $10.94M | $25.84M | $7.86M | +173.2% |
| Working capital | $9.11M | $1.98M | $8.89M | $23.64M | $4.41M | +360.6% |
| Net tangible assets | $10.82M | $3.79M | $10.62M | $25.41M | $7.34M | +185.5% |
| Shares issued | 190.76M | 164.88M | 131.10M | 130.92M | 101.83M | +15.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$11.69M | -$13.91M | -$16.27M | -$10.40M | -$4.44M | — | +16.0% |
| Depreciation & amortisation | $224.00K | $222.00K | $209.00K | $220.00K | $222.00K | — | +0.9% |
| Stock-based compensation | $1.69M | $1.41M | $1.17M | $1.15M | $1.14M | — | +20.0% |
| Change in working capital | -$515.00K | -$1.71M | -$45.00K | -$692.00K | -$709.00K | — | +69.9% |
| Operating cash flow | -$11.30M | -$12.10M | -$12.58M | -$10.89M | -$10.55M | — | +6.6% |
| Capital expenditure | -$21.00K | -$215.00K | -$51.00K | -$28.00K | -$25.00K | — | +90.2% |
| Investing cash flow | -$21.00K | -$215.00K | -$51.00K | -$28.00K | -$25.00K | — | +90.2% |
| Share buybacks | $0 | -$17.00K | — | — | $0 | $0 | +100.0% |
| Financing cash flow | $16.85M | $5.49M | $2.00K | $27.13M | $16.46M | — | +207.0% |
| Free cash flow | -$11.32M | -$12.32M | -$12.63M | -$10.92M | -$10.57M | — | +8.1% |
| End cash position | $33.40M | $27.88M | $34.70M | $47.33M | $31.12M | — | +19.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.06 | -0.06 | -9.1% |
| Mar 2026 | -0.06 | -0.07 | -10.5% |
| Dec 2025 | -0.09 | -0.10 | -15.4% |
| Sep 2025 | -0.09 | -0.10 | -15.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.06 | 3 | $1.64M | +35.5% |
| Next quarter | -0.06 | 4 | $1.95M | +29.8% |
| Current year | -0.24 | 3 | $6.30M | +33.9% |
| Next year | -0.17 | 4 | $16.71M | +165.2% |
Analyst targets & ownership
Mean target$4.00
High target$9.50
Low target$2.00
Implied upside566.67%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy2 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders26.50%
Held by institutions32.74%
Institutions holding142
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.73
-18.08% from price
SMA 20
0.77
-22.33% from price
SMA 50
0.89
-32.33% from price
SMA 100
0.95
-36.73% from price
SMA 200
1.08
-44.60% from price
EMA 12
0.72
-16.45% from price
EMA 26
0.79
-24.31% from price
EMA 50
0.86
-30.19% from price
RSI (14)
25.0
Oversold
MACD (12,26,9)
-0.07
Hist -0.02
ATR (14)
0.07
11.87% of price
Realised vol 30D
73.5%
Annualised
Bollinger upper
0.94
20, 2σ
Bollinger lower
0.60
20, 2σ
50 / 200 cross
Death
0.89 vs 1.08
Trend bias
Below 200
-44.60%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.25
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
73.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-59.7%
Peak to trough
Max drawdown 5Y
-95.0%
Peak to trough
ATR 14
0.07
11.87% of price
Beta (reported)
1.12
5Y monthly, from filing
Short interest
Shares short
12.83M
Prior 12.83M
Change vs prior
-0.0%
Shorts covering
% of float
8.64%
Normal
% of shares out
6.72%
Against total outstanding
Days to cover
13.9
Crowded exit
Float
140.76M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Aug 17, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 8, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| May 15, 26 | Maxim Group | MAINTAINED | Buy | Buy |
| May 15, 26 | BTIG | MAINTAINED | Buy | Buy |
| Apr 9, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Mar 30, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 26, 26 | Needham | MAINTAINED | Buy | Buy |
| Dec 10, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Nov 13, 25 | Needham | MAINTAINED | Buy | Buy |
| Oct 6, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Sep 10, 25 | BTIG | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-22
Corporate Changes & Voting Matters
8-K · 2026-08-13
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-05-14
Periodic Financial Reports
10-Q · 2026-05-13
Proxy Statements
DEF 14A · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-04-24
Headlines
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
PR Newswire · 15d ago
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript
Motley Fool · 48d ago
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
MarketBeat · 53d ago
PAVmed Inc. Q2 2026 Earnings Call Summary
Moby · 54d ago
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
PR Newswire · 54d ago
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary
Moby · 54d ago
Lucid Diagnostics Inc (LUCD) (Q2 2026) Earnings Call Highlights: Strategic Pivot to High-Value ...
GuruFocus.com · 54d ago
Lucid Diagnostics Q2 Earnings Call Highlights
MarketBeat · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.